Artelo Biosciences, Inc. ARTL

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

GlobeNewswire Inc. · 4d ago

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire Inc. · 110d ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Benzinga · 291d ago

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

GlobeNewswire Inc. · 373d ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

GlobeNewswire Inc. · 387d ago

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

GlobeNewswire Inc. · 408d ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

GlobeNewswire Inc. · 647d ago

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire Inc. · 682d ago

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

GlobeNewswire Inc. · 774d ago

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

GlobeNewswire Inc. · 780d ago

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

GlobeNewswire Inc. · 799d ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

GlobeNewswire Inc. · 816d ago

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

GlobeNewswire Inc. · 817d ago

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

GlobeNewswire Inc. · 858d ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

GlobeNewswire Inc. · 907d ago

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

GlobeNewswire Inc. · 922d ago

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

GlobeNewswire Inc. · 989d ago

Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia

GlobeNewswire Inc. · 1018d ago

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

GlobeNewswire Inc. · 1039d ago

Why Toro Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga · 1045d ago

Why WestRock Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Benzinga · 1045d ago

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

GlobeNewswire Inc. · 1095d ago

Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11

GlobeNewswire Inc. · 1104d ago

Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium

GlobeNewswire Inc. · 1117d ago

Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium

GlobeNewswire Inc. · 1118d ago